Aptevo Therapeutics (APVO) Competitors $1.98 +0.57 (+40.43%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.11 (+5.30%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. CING, THAR, CTXR, LIXT, FNCH, QTTB, AYTU, LEXX, SONN, and LSTAShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Cingulate (CING), Tharimmune (THAR), Citius Pharmaceuticals (CTXR), Lixte Biotechnology (LIXT), Finch Therapeutics Group (FNCH), Q32 Bio (QTTB), Aytu BioPharma (AYTU), Lexaria Bioscience (LEXX), Sonnet BioTherapeutics (SONN), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Its Competitors Cingulate Tharimmune Citius Pharmaceuticals Lixte Biotechnology Finch Therapeutics Group Q32 Bio Aytu BioPharma Lexaria Bioscience Sonnet BioTherapeutics Lisata Therapeutics Aptevo Therapeutics (NASDAQ:APVO) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Is APVO or CING more profitable? Cingulate's return on equity of -232.16% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -675.52% -175.68% Cingulate N/A -232.16%-132.07% Does the media favor APVO or CING? In the previous week, Aptevo Therapeutics had 2 more articles in the media than Cingulate. MarketBeat recorded 6 mentions for Aptevo Therapeutics and 4 mentions for Cingulate. Cingulate's average media sentiment score of 0.95 beat Aptevo Therapeutics' score of 0.76 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptevo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, APVO or CING? Aptevo Therapeutics has a beta of 5.77, suggesting that its share price is 477% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.76, suggesting that its share price is 176% less volatile than the S&P 500. Which has preferable valuation and earnings, APVO or CING? Cingulate has lower revenue, but higher earnings than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo Therapeutics$3.11M2.09-$24.13MN/AN/ACingulateN/AN/A-$15.55M-$4.10-0.86 Do insiders and institutionals believe in APVO or CING? 8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 0.0% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate APVO or CING? Aptevo Therapeutics currently has a consensus target price of $219,040.00, indicating a potential upside of 11,062,526.26%. Cingulate has a consensus target price of $26.25, indicating a potential upside of 645.74%. Given Aptevo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aptevo Therapeutics is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCingulate beats Aptevo Therapeutics on 7 of the 13 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.51M$3.14B$5.81B$10.36BDividend YieldN/A2.37%5.86%4.62%P/E RatioN/A21.3676.8726.99Price / Sales2.09248.62449.2288.69Price / CashN/A45.4837.2260.63Price / Book0.039.6913.836.37Net Income-$24.13M-$52.92M$3.29B$271.46M7 Day Performance32.00%1.44%0.94%2.34%1 Month Performance-4.35%6.02%5.31%7.77%1 Year Performance-99.96%12.89%84.25%31.08% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics3.1492 of 5 stars$1.98+40.4%$219,040.00+11,062,526.3%-100.0%$6.51M$3.11M0.0050Analyst UpgradeGap UpHigh Trading VolumeCINGCingulate2.8953 of 5 stars$3.75-3.8%$26.25+600.0%-28.4%$21.11MN/A-0.9120News CoverageTHARTharimmune2.2983 of 5 stars$2.96-19.6%$17.00+474.3%-10.4%$20.94MN/A-0.492Gap UpCTXRCitius Pharmaceuticals2.1658 of 5 stars$1.22-0.8%$53.00+4,244.3%-90.6%$20.92MN/A0.0020Short Interest ↑LIXTLixte Biotechnology0.9214 of 5 stars$4.32-5.5%N/A+163.1%$20.84MN/A-3.354FNCHFinch Therapeutics Group1.4088 of 5 stars$12.70flatN/A+7.8%$20.40MN/A-1.44190Positive NewsShort Interest ↓Gap DownQTTBQ32 Bio2.2057 of 5 stars$1.75+4.8%$12.17+595.2%-96.3%$20.37M$1.16M-0.4139AYTUAytu BioPharma3.6854 of 5 stars$2.27+0.9%$10.00+340.5%-8.3%$20.20M$81M-3.15160News CoverageUpcoming EarningsLEXXLexaria Bioscience3.79 of 5 stars$1.04+1.0%$4.00+284.6%-62.9%$20.15M$460K-1.557Positive NewsShort Interest ↓Gap DownSONNSonnet BioTherapeutics1.9886 of 5 stars$3.29+15.4%$20.00+507.9%-7.2%$19.46M$20K0.0010LSTALisata Therapeutics3.2399 of 5 stars$2.18+0.5%$23.50+978.0%-26.5%$19M$1M-0.9830Short Interest ↓Gap Down Related Companies and Tools Related Companies CING Alternatives THAR Alternatives CTXR Alternatives LIXT Alternatives FNCH Alternatives QTTB Alternatives AYTU Alternatives LEXX Alternatives SONN Alternatives LSTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APVO Stock Alerts